Compare Eli Lilly And Co (LLY) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Palo Alto Networks Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Palo Alto Networks Inc trades at $418.78 (market cap $331.76B). The key difference: Eli Lilly And Co is far larger — about 3.1× Palo Alto Networks Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Palo Alto Networks Inc for 82 Days on average.
| LLY | PANW | |
|---|---|---|
Market Cap | $1.04T | $331.76B |
Volume | 3,064,878 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $1.28K | $419.91 |
52-Week Low | $799.57 | $141.67 |
Typical Hold Time | 93 Days | 82 Days |
Enterprise Value | $1.09T | $331.19B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Palo Alto Networks trades at $398.50, down 1.7% today but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth continues at $9.22 billion for 2025, though profitability metrics show mixed results with high gross margins but modest net income margins. The company's AI security initiatives are driving positive media coverage and investor optimism.
Outlook remains positive given strong analyst consensus (72% buy ratings) and AI-driven cybersecurity demand, but premium valuations and execution risks warrant caution. The stock trades near its consensus price target of $398.70, suggesting limited near-term upside without significant earnings acceleration or multiple expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
